Tag: Kadmon Holdings Inc (NASDAQ: KDMN)

Business

Kadmon Holdings Inc (NASDAQ: KDMN) Gets FDA Approval For Their Chronic Graft Versus Host Disease Drug

Kadmon Holdings Inc (NASDAQ: KDMN) recently announced that the FDA (Food and Drug Administration) finally approved their REZUROCK (belumosudil) 200 mg once a day in treating adult and pediatric patients above 12 years old with chronic graft versus host disease (cGVHD). The drug is to be used after two failed […]

Business

Kadmon Holdings Inc (NASDAQ: KDMN) Announces That REZUROCK™ Clinical Trial Results Published

Kadmon Holdings Inc (NASDAQ: KDMN), in a statement, announced that pivotal trial data from the ROCKstar clinical trial of REZUROCK™ (belumosudil) is published in the journal Blood. In addition, the company was in the news for receiving FDA approval of its REZUROCK™ drug ahead of the deadline. The FDA-approved drug […]